Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Summary

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2021-06-30

Primary completion

2027-01-31

Completion

2028-01-31

Drugs

Indications